The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer

Wild-type EGFR Is Stabilized by Direct Interaction with HSP90 in Cancer Cells and Tumors

(2015) Aarif Ahsan et al.   NEOPLASIA

Ganetespib and HSP90: Translating Preclinical Hypotheses into Clinical Promise

(2014) D. A. Proia et al.   CANCER RESEARCH

Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review

(2013) Abdul-Rahman Jazieh et al.   Annals of Thoracic Medicine

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer

(2013) Naomi Ono et al.   CANCER SCIENCE

Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies

(2013) S. Carrera et al.   Clinical & Translational Oncology

A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer

(2013) M. A. Socinski et al.   CLINICAL CANCER RESEARCH

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients WithEGFRWild-Type Non–Small-Cell Lung Cancer: The Never-Ending Story

(2013) Francesco Gelsomino et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non–Small-Cell Lung Cancer

(2013) Scott A. Laurie et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?

(2013) Jacek Jassem et al.   LANCET ONCOLOGY

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

(2013) Marina Chiara Garassino et al.   LANCET ONCOLOGY

Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non-Small Cell Lung Cancer

(2012) T. Shimamura et al.   CLINICAL CANCER RESEARCH

Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

(2012) L. Neckers et al.   CLINICAL CANCER RESEARCH

Role of Erlotinib in the Treatment of Non-Small Cell Lung Cancer

(2012) Bilal Piperdi et al.   DRUGS

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models

(2012) David A. Proia et al.   INVESTIGATIONAL NEW DRUGS

Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer

(2012) Kang-Yi Su et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting KRAS-Mutant Non-Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib

(2012) J. Acquaviva et al.   MOLECULAR CANCER THERAPEUTICS

Lung cancer: New biological insights and recent therapeutic advances

(2011) Suresh S. Ramalingam et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

(2011) W. Ying et al.   MOLECULAR CANCER THERAPEUTICS

Targeting EGFR in non-small-cell lung cancer: Lessons, experiences, strategies

(2011) Giulia M. Stella et al.   RESPIRATORY MEDICINE

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities

(2011) Elizabeth M. Gaughan et al.   Therapeutic Advances in Medical Oncology

Global Patterns of Cancer Incidence and Mortality Rates and Trends

(2010) A. Jemal et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

(2010) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

HSP90 at the hub of protein homeostasis: emerging mechanistic insights

(2010) Mikko Taipale et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Future Scenarios for the Treatment of Advanced Non-Small Cell Lung Cancer: Focus on Taxane-Containing Regimens

(2010) F. Grossi et al.   ONCOLOGIST

Beyond Doublet Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Combination of Targeted Agents with First-Line Chemotherapy

(2009) Roy S. Herbst et al.   Clinical Lung Cancer

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

(2009) A F Gazdar   ONCOGENE

Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance

(2008) T. Shimamura et al.   CANCER RESEARCH

Heat Shock Protein 90 as a Drug Target: Some Like It Hot

(2008) U. Banerji   CLINICAL CANCER RESEARCH

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE

Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions

(2008) S. Ramalingam et al.   ONCOLOGIST